Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dapagliflozin in Allo-HCT for aGVHD
Sponsor: The First Affiliated Hospital of Soochow University
Summary
The goal of this clinical trial is to learn if Dapagliflozin could prevent acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with haploidentical or unrelated donor and to assess its safety. The main questions it aims to answer are: Dose Dapagliflozin lower the cumulative incidence of aGVHD? What medical problems do participants undergoing allo-HCT from haploidentical or unrelated donor have when taking Dapagliflozin? Researchers will document the occurrence of graft-versus-host disease, hematopoietic reconstitution, survival rates and adverse effects. Participants will take Dapagliflozin every day in -1 to 14 days.
Official title: Dapagliflozin for Preventing Acute Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Prospective, Single-Arm Study
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2025-04-26
Completion Date
2026-12-31
Last Updated
2025-06-05
Healthy Volunteers
No
Conditions
Interventions
Dapagliflozin (DAPA)
Participants will take Dapagliflozin 10mg every day in -1 to 14 days
Locations (1)
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China